Cero Therapeutics Completes First Cohort of Phase 1 Trial for CER-1236 in AML, Initiates Next Dose Escalation
Reuters
Oct 13
Cero <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Completes First Cohort of Phase 1 Trial for CER-1236 in AML, Initiates Next Dose Escalation
CERo Therapeutics Holdings Inc. has announced the completion of the first cohort in its Phase 1 clinical trial of CER-1236, a cellular immunotherapy candidate for patients with acute myeloid leukemia (AML). According to the company, no dose-limiting toxicities were observed in the initial cohort, and cell expansion consistent with preclinical expectations was reported. The completion of the first cohort allows the study to progress to the next planned dose level, pending regulatory approval. CERo Therapeutics stated that it is currently focused on advancing this dose-escalation trial and is not actively seeking acquisition or partnership opportunities at this time. Clinical results from the study have been collected to date; however, the company did not specify when further results will be presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544259-en) on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.